Clinical Trial: Adjunctive Glycine for Obsessive Compulsive Disorder

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Adjunctive Glycine for Obsessive Compulsive Disorder

Brief Summary: The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Detailed Summary: Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given orally in adequate dosages, can have specific effects on one particular glutamate receptor molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind protocol will have study participants who suffer with OCD take either a glycine preparation or placebo for 12 weeks. Clinical measures (e.g., Y-BOCS, NIMH-OC) will be recorded at each visit to determine whether those taking the glycine experience clinical benefit.
Sponsor: Nathan Kline Institute for Psychiatric Research

Current Primary Outcome: Y-BOCS (Yale-Brown Obsessive Compulsive Scale) [ Time Frame: 12 weeks after baseline ]

Original Primary Outcome: Y-BOCS (Yale-Brown Obsessive Compulsive Scale)

Current Secondary Outcome:

  • NIMC-OC scale [ Time Frame: 12 weeks after baseline ]
  • CGI-Improvement [ Time Frame: 12 weeks after baseline ]
  • QLS(Quality of Life Scale) [ Time Frame: 12 weeks after baseline ]
  • Sheehan Disability Scale [ Time Frame: 12 weeks after baseline ]


Original Secondary Outcome:

  • NIMC-OC scale
  • CGI-Improvement
  • QLS(Quality of Life Scale)
  • Sheehan Disability Scale


Information By: Nathan Kline Institute for Psychiatric Research

Dates:
Date Received: November 28, 2006
Date Started: June 2004
Date Completion:
Last Updated: December 15, 2016
Last Verified: December 2016